Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
J Vet Intern Med. 2013 Mar-Apr;27(2):377-81. doi: 10.1111/jvim.12040. Epub 2013 Feb 9.
Transdermal methimazole is an acceptable alternative to oral treatment for hyperthyroid cats. There are, however, no studies evaluating the duration of T4 suppression after transdermal methimazole application. Such information would be valuable for therapeutic monitoring.
To assess variation in serum T4 concentration in hyperthyroid cats after once- and twice-daily transdermal methimazole administration.
Twenty client-owned cats with newly diagnosed hyperthyroidism.
Methimazole was formulated in a pluronic lecithin organogel-based vehicle and applied to the pinna of the inner ear at a starting dose of 2.5 mg/cat q12h (BID group, 10 cats) and 5 mg/cat q24h (SID group, 10 cats). One and 3 weeks after starting treatment, T4 concentrations were measured immediately before and every 2 hours after gel application over a period of up to 10 hours.
Significantly decreased T4 concentrations were observed in week 1 and 3 compared with pretreatment concentrations in both groups. All cats showed sustained suppression of T4 concentration during the 10-hour period, and T4 concentrations immediately before the next methimazole treatment were not significantly different compared with any time point after application, either in the BID or SID groups.
Because transdermal methimazole application led to prolonged T4 suppression in both the BID and SID groups, timing of blood sampling does not seem to be critical when assessing treatment response.
透皮甲巯咪唑是治疗甲状腺功能亢进猫的一种可接受的口服替代疗法。然而,目前尚无研究评估透皮甲巯咪唑给药后 T4 抑制的持续时间。这种信息对于治疗监测很有价值。
评估甲状腺功能亢进猫经透皮甲巯咪唑每日 1 次和 2 次给药后血清 T4 浓度的变化。
20 只新诊断为甲状腺功能亢进的患宠猫。
将甲巯咪唑制成泊洛沙姆卵磷脂有机凝胶载体,并以 2.5 mg/只猫 q12h(BID 组,10 只猫)和 5 mg/只猫 q24h(SID 组,10 只猫)的起始剂量应用于耳内的耳甲。在开始治疗后的第 1 周和第 3 周,在凝胶给药后 10 小时内,在给药前即刻和每 2 小时测量 T4 浓度。
与治疗前相比,两组在第 1 周和第 3 周 T4 浓度均显著降低。所有猫在 10 小时内持续抑制 T4 浓度,并且 BID 或 SID 组中,下一次甲巯咪唑治疗前的 T4 浓度与给药后任何时间点均无显著差异。
由于透皮甲巯咪唑应用导致 BID 和 SID 组的 T4 抑制持续时间延长,因此在评估治疗反应时,采血时间似乎并不关键。